The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.
Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.
RBM is, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site- and patient-centric environment.
The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.
Takeda's R&D shake-up continues to rumble on, with the Japanese drugmaker signing a wide-ranging deal that will see it work closely with researchers…
DNA-encoded library technology expert HitGen just inked a multiyear, multitarget drug discovery deal with Aduro Biotech.
The collaboration aims to drive forward research into treatments for the rare ROS1 gene mutation by gathering tissue samples from patients.
The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.
Celgene has decided it is best served by picking up the choicest fruits of the collaboration while leaving Sutro to go forward independently.
The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.
Biotech VC Jonathan Silverstein has unveiled the next development in his quest to find a cure for Parkinson's with GBA.